Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Sat, 09/28/19 - 04:49 pm
Tags:
Roche, Avastin, ovarian cancer, AstraZeneca, Merck, Lynparza, ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
Thu, 09/26/19 - 12:33 pm
Tags:
GSK, AstraZeneca, PARP inhibitors, ESMO, Lynparza, Zejula
Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program
Fierce Pharma
Wed, 09/25/19 - 11:30 pm
Tags:
China, Sanofi, AstraZeneca, Eli Lilly, drug pricing
Deepening US footprint, AstraZeneca-partnered French biotech Innate shoots for $100M IPO
Endpoints
Mon, 09/23/19 - 10:49 am
Tags:
Innate Pharma, IPOs, AstraZeneca, blood cancer, solid tumors
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
Tags:
JNJ, daratumumab, Urogen, Rhythm Pharmaceuticals, Anavex, Aravive Biologics, TrovaGene, Incyte, AstraZeneca, Roche, Amgen, Aslan, G1 Therapeutics, GSK, Calithera Biosciences, Seattle Genetics, Immunomedics, Checkpoint Therapeutics, Aileron Therapeutics, Genocea Biosciences, AbbVie, Zymeworks
EASD: AstraZeneca piles on supporting evidence for Farxiga use in heart failure
Fierce Pharma
Thu, 09/19/19 - 07:59 pm
Tags:
AstraZeneca, Farxiga, EASD, heart failure
AstraZeneca diabetes drug granted fast track status for heart failure treatment
Yahoo/Reuters
Mon, 09/16/19 - 09:28 am
Tags:
AstraZeneca, Farxiga, heart failure, diabetes, FDA, fast track
Real world evidence, digital partnerships and the future of pharma
Pharmaforum
Fri, 09/13/19 - 10:51 am
Tags:
digital pharma, AstraZeneca, RWE, real world evidence
Drug companies pay for exclusive access to UK genetic data
Biopharma Dive
Thu, 09/12/19 - 11:35 am
Tags:
UK, genetic database, Amgen, AstraZeneca, JNJ, GSK
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
Mon, 09/9/19 - 08:08 pm
Tags:
WCLC, lung cancer, KRAS, AMG 510, Amgen, RET, Merck, Keytruda, AstraZeneca, Imfinzi, Blueprint Medicines, Eli Lilly
PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi
Endpoints
Mon, 09/9/19 - 10:24 am
Tags:
AstraZeneca, clinical trials, Imfinzi, Small-Cell Lung Cancer
AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study
Fierce Pharma
Fri, 09/6/19 - 12:38 pm
Tags:
AstraZeneca, Farxiga, drug reps, heart failure
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
Tags:
ESMO, PARP inhibitors, Lynparza, AstraZeneca, ovarian cancer, GSK, Zejula
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
Pharmaforum
Thu, 09/5/19 - 10:15 am
Tags:
AstraZeneca, Theragnostics, PARP inhibitors, diagnostics, cancer
ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut
Fierce Pharma
Wed, 09/4/19 - 11:48 am
Tags:
AstraZeneca, Farxiga, ESC
AZ gets China nod for Tagrisso in first-line lung cancer
Pharmaforum
Wed, 09/4/19 - 11:22 am
Tags:
AstraZeneca, China, Tagrisso, non-small cell lung cancer
Heart failure results could unlock key market for Farxiga – AZ
Pharmaforum
Mon, 09/2/19 - 12:22 pm
Tags:
AstraZeneca, heart failure, diabetes, Farxiga
One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint
Fierce Biotech
Thu, 08/29/19 - 10:30 am
Tags:
AstraZeneca, clinical trials, anifrolumab, systemic lupus erythematosus, lupus
AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis
Pharmaceutical Business Review
Thu, 08/29/19 - 10:28 am
Tags:
AstraZeneca, Fasenra, orphan drugs, FDA, eosinophilic esophagitis
AstraZeneca respiratory business gets boost from 3-drug inhaler results
Yahoo/Reuters
Wed, 08/28/19 - 10:52 am
Tags:
AstraZeneca, Fasenra, Breztri, COPD

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.